AIBN Professor Trent Munro is part of a new biotechnology company aiming to treat Type 2 diabetes using saliva from parasitic worms.
Professor Munro has been appointed an Advisory Board member of Macrobiome Therapeutics, spun out of James Cook University (JCU) research and a recipient of $2.2 million in new federal government funding.
His AIBN team and the National Biologics Facility (NBF) have conducted collaborative research with JCU lead researcher Professor Alex Loukas to develop potentially game-changing therapeutics.